Clinical Study

Hepatitis B Infection in Microbiology Laboratory Workers: Prevalence, Vaccination, and Immunity Status

Arun Kumar Jha,1 Sanjim Chadha,1 Preena Bhalla,1 and Sanjeev Saini2

1 Department of Microbiology, Maulana Azad Medical College, University of Delhi, Bahadur Shah Zafar Marg, New Delhi 110002, India
2 Central Surveillance Unit, Integrated Disease Surveillance Project (IDSP), National Center for Disease Control (NCDC), New Delhi 110054, India

Correspondence should be addressed to Arun Kumar Jha, dr_jhauc2k@yahoo.co.in

Received 2 August 2012; Accepted 18 November 2012

Academic Editor: Piero Luigi Almasio

Copyright © 2012 Arun Kumar Jha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The risk of contracting HBV by health care workers (HCW) is four-times greater than that of general adult population. Studies have demonstrated that vaccine-induced protection persists at least 11 years. High risk groups such as HCWs should be monitored and receive a booster vaccination if their anti-HBsAb levels decrease below 10 mIU/mL. In view of the above this study was undertaken to assess the HBV vaccination of the HCWs and their immunological response. Seventy-two HCWs of the Department of Microbiology, Maulana Azad Medical College, New Delhi, India, were recruited and blood sample was drawn for serological tests (HBSAg, anti-HCV, anti-HBsAb, anti-HBeAb, and anti-HBcAb). Anti-HBs titers of >10 mIU/mL were considered protective. Thirty-four (47.3%) of the participants were completely vaccinated with three doses. 25 (73.5%) of the participants with complete vaccination had protective anti-HBsAb levels as against 8 (53.3%) of those with incomplete vaccination and 9 (39.1%) of those who were not vaccinated at all. One of our participants was acutely infected while 29 participants were susceptible to infection at the time of the study. All HCWs should receive three doses of the vaccine and be monitored for their immune status after every five years. Boosters should be administered to those who become susceptible.

1. Introduction

Hepatitis B is a serious infectious disease of the liver which affects millions of people worldwide. More than 2 billion people living today have been infected with Hepatitis B virus (HBV) at some time in their lives and about 350 million people are carriers of the virus [1]. India has intermediate endemicity of Hepatitis B, with Hepatitis B surface antigen (HBsAg) prevalence between 2% and 7%. The number of HBsAg carriers in India has been estimated to be over 50 millions [2, 3].

Throughout the world, millions of healthcare professionals work in health institutions and it is estimated that 600,000 to 800,000 cut and puncture injuries occur among them per year, of which approximately 50% are not registered [4]. The risk of contracting HBV by health care workers (HCWs) is four-times greater than that of general adult population [5]. The highest rates are seen among dentists, physicians, laboratory workers, dialysis workers, cleaning service employees, and nurses [6].

Blood contains the highest HBV titers of all body fluids and is the most important vehicle of transmission in the health care setting. Avoiding occupational blood exposure is the primary preventive means for the transmission of HBV. Immunization and after exposure management are integral components of a complete infection control program for this group [7].

Protection (defined as antihepatitis B virus surface antigen antibodies (anti-HBsAb) level ≥10 mIU/mL) following first, second, and third doses of the recombinant vaccine has been reported to be 20–30%, 75–80%, and 90–95%, respectively [8, 9]. Studies have demonstrated that vaccine-induced protection persists at least 11 years and booster vaccination for immunocompetent children and adults is not
Address correspondence to: Dr. Rekha Choudhary, Resident Doctor, Department of Microbiology, Maulana Azad Medical College, New Delhi, India.

The vaccine while 15 (20.8%) of them had not completed the vaccination schedule, and 23 (31.9%) were not vaccinated at all (Table 1).

Table 1: Status of HBV vaccination of participants (n = 72).

| Vaccination status | Number | Percentage |
|--------------------|--------|------------|
| Complete vaccination | 34     | 47.3%      |
| Incomplete vaccination | 15     | 20.8%      |
| Not vaccinated       | 23     | 31.9%      |

Recommended for long-term protection [10, 11]. Immunocompromised patients and high risk groups such as health care workers, however, should be monitored and receive a booster vaccination if their anti-HBsAb levels decrease below 10 mIU/mL [12, 13].

In our study we determined the HBV serological status of microbiology laboratory workers in a tertiary care hospital in New Delhi, India. We also analyzed the HBV vaccination of the laboratory workers and their long-term immunological response to vaccination in view of administering a booster dose to those with anti-HBsAb levels <10 mIU/mL.

2. Materials and Methods

This study was conducted in the Department of Microbiology, Maulana Azad Medical College, New Delhi, India. Seventy-two participants were enrolled for the study in the age group 20–70 years. Participants consisted of Professors, Resident Doctors, Ph.D. scholars, laboratory technicians and laboratory attendants working in the Department of Microbiology. After obtaining an informed written consent from each participant, all laboratory workers were asked to complete a questionnaire consisting of their age, gender, Hepatitis B vaccination status, their job description, and educational level.

Blood sample was drawn from each participant under strict aseptic precautions in a plain vacutainer. Blood was allowed to clot and serum was separated and stored at −20°C until further testing. Serological tests (HBsAg, antihepatitis C virus antibodies (anti-HCV), anti-HBsAb, anti Hepatitis B virus e antigen antibody (anti-HBeAb), and anti Hepatitis B virus core antigen antibody (anti-HBcAb)) were performed using commercially available ELISA kits according to the manufacturer’s instructions. Anti-HBs titers of >10 mIU/mL were considered protective.

3. Results

A total of 72 participants were recruited including 40 males (55.6%) and 32 females (44.4%) with a male female ratio of 1.25:1. The median age of study subjects was 31.5 years (range 20–70 years) with 20–40 years being the most common age group. Fifteen (20.8%) of our participants were laboratory attendants, 21 (29.2%) were laboratory technicians, 10 (13.8%) were Ph.D. scholars, 18 (25%) were resident doctors and 4 (5.6%) were Professors in Department of Microbiology. Thirty-four (47.3%) of the participants were completely vaccinated for hepatitis B with three doses of the vaccine while 15 (20.8%) of them had not completed the vaccination schedule, and 23 (31.9%) were not vaccinated at all.

Out of the 34 subjects who were completely vaccinated, 2 had received vaccination <5 years ago, 17 were vaccinated 5–10 years ago and 15 were vaccinated >10 years before the study. High titers of anti-HBsAb (>100 mIU/mL) were seen in 100% of the cases in the first group (<5 years since vaccination) and 41.2% and 33.4% in the other two groups, respectively (Table 3; P value = 0.071).

Table 4 shows the status of vaccination in relation to the professional designation in the department. 59.4% of our staff with a medical degree was completely vaccinated as against 37.5% of other staff in the department.

Table 5 shows the hepatitis B serologic tests of all study subjects (n = 72). Twenty-nine (40.3%) participants were susceptible to infection at the time of the study irrespective of their vaccination status. Seven (9.8%) were immune due to natural infection (recent and remote) while 35 (48.6%) were immune due to hepatitis B vaccination. Only one of our participants was acutely infected at the time of the study. Three (4.2%) had isolated positive anti-HBCAb with negative HBs Ag, anti-HBsAb, and anti-HBeAb. None of the participants demonstrated positive anti-HCV at the time of the study.

4. Discussion

Vaccination is an important measure in preventing HBV infection in health care workers. In our study only 47.3% had received three doses of hepatitis B vaccine, while 20.8% had incomplete vaccination and 31.9% were not vaccinated at all. These observations indicate that hepatitis B vaccination coverage is still inadequate in our country even among high risk groups such as laboratory workers. The main reason behind this could be due to an absence of vaccination policies established by the hospital management and also a lack of awareness or inclination on the part of Laboratory workers. Surprisingly even in some developed countries like Sweden, only 40% health care workers reported that they were fully vaccinated and 21% had not been vaccinated at all [14].

An interesting observation in our study was that 59.4% of the doctors had received complete vaccination while 37.5% of other staff (laboratory attendants, assistants, and technicians) was completely vaccinated (Table 4; P value = 0.136). This contrast in vaccination coverage can be explained by the difference in education and awareness among the two groups. 28.1% of the doctors were not vaccinated at all and this is due to the fact that this group also includes Ph.D. scholars who have not yet worked in a medical hospital before joining this degree course and therefore do not feel the need to get themselves vaccinated. In a study done in AIIMS, New Delhi, 96% doctors were vaccinated [15].
The prevalence of acute HBV infection (HBsAg positive) in our laboratory workers was found to be 1.4% (1/72). This person was a 58-year-old laboratory technician. However, since he was not directly involved in collection of blood or serological testing of blood samples, his infection may not have been acquired by him due to his occupation. The percentage positivity of HBsAg in another study conducted in GB Pant Hospital, New Delhi was found to be 1% [16].

Twenty-five (73.5%) of our study participants with complete vaccination had protective (>10 mIU/mL) anti-HBsAb levels as against 8 (53.3%) of those with incomplete vaccination and 9 (39.1%) of those who were not vaccinated had protective anti-HBsAb levels. These findings show that 26.5% of the laboratory workers with complete vaccination had not achieved protective antibody levels and were still susceptible to acquire infection. These workers were asked to take a booster dose of hepatitis B vaccine. However 39.1% of those who were not vaccinated at all attained protective antibody levels probably due to the acquisition of natural infection sometime in the past which conferred natural immunity to these individuals. Another important observation that our study highlights is that 40.3% of our laboratory workers were not immune and were still at risk of hepatitis B infection. This again points to the lapse of the higher authorities for not creating a vaccination strategy for laboratory workers and also not increasing awareness among health care workers for getting them vaccinated. Our findings are similar to a study conducted on nursing students in a tertiary care hospital in Chandigarh in which of the ones who had received a complete course of HBV vaccination 82.2% showed protective levels. The protective anti-HBs antibody levels in students who were unvaccinated showed protective levels. The protective anti-HBs antibody levels in students who were unvaccinated varied between 82.2% and 93.6% for those who did not have complete vaccination [17].

Three (4.2%) of our study participants showed isolated positive anti-HBc serological reaction. This could be due to a false positive anti-HBc reaction or subjects being in the window period of infection. False positive anti-HBc results may occur when nonspecific IgM binds to the HBcAg peptides used as a probe in the assay. As with any screening assay, the anti-HBc assay has greater specificity in high risk populations. Thus, if a patient with risk factors for hepatitis B infection demonstrates isolated anti-HBc in serum, a false positive result would be less likely than in a patient without risk factors but the possibility still exists [18, 19]. These cases were referred for HBV DNA testing and IgM anti-HBcAb testing to determine whether they were in the window phase, or have occult HBV infection. A study conducted in a Brazilian university hospital in 2005 showed that 9.4% of HCWs had positive anti-HBc [20].

In our study, protective anti-HBsAb titers were seen in 100% of the cases who were completely vaccinated <5 years before the study and in 58.8% and 86.6% of those who had received a complete course of vaccination 5–10 years and >10 years ago, respectively. Another study from Iran has shown that 89% of subjects with complete vaccination less than five years before achieved protective anti-HBs titers and 13.9% cases who had been vaccinated within 5–10 years had positive serology. 57.9% of HCWs who had been vaccinated >10 years before had long-lasting immunity against HBV infection [21].

5. Conclusions

From this study, we concluded that at the time of recruitment all laboratory workers should be assessed for the presence of HBsAg and anti-HBsAb titers. All laboratory workers should receive complete three doses of the hepatitis B vaccine and screened for the anti-HBsAb levels. Those who do not achieve the protective anti-HBsAb titers should be given additional doses. All laboratory workers should then be monitored for their immune status every five years and booster doses should be administered to those who have become
Table 4: Status of vaccination in relation to the designation (n = 72).

| Designation                                      | Complete vaccination (%) | Incomplete vaccination (%) | Not vaccinated (%) | P value (chi-square test) |
|-------------------------------------------------|--------------------------|---------------------------|-------------------|--------------------------|
| Laboratory Attendants, assistants, and technicians (40) | 15 (37.5)                | 11 (27.5)                 | 14 (35)           | 0.136                    |
| Resident doctors, Ph.D. scholars, and professors (32) | 19 (59.4)                | 4 (12.5)                  | 9 (28.1)          |                          |

Table 5: Results of hepatitis B serologic tests of all study subjects (n = 72).

| Serologic test | Result        | Number of study subjects (%) | Interpretation                             |
|----------------|---------------|------------------------------|--------------------------------------------|
| HBsAg          | Negative      | 26 (36.1)                    | Susceptible                                |
| Anti-HBsAb     | Negative      |                             |                                            |
| Anti-HBcAb     | Negative      |                             |                                            |
| Anti-HBeAb     | Negative      |                             |                                            |
| HBsAg          | Positive      | 4 (5.6)                      | Immune due to recent infection             |
| Anti-HBsAb     | Positive      |                             |                                            |
| Anti-HBcAb     | Positive      |                             |                                            |
| Anti-HBeAb     | Positive      |                             |                                            |
| HBsAg          | Negative      | 3 (4.2)                      | Immune due to remote infection             |
| Anti-HBsAb     | Positive      |                             |                                            |
| Anti-HBcAb     | Negative      |                             |                                            |
| Anti-HBeAb     | Negative      |                             |                                            |
| HBsAg          | Positive      | 35 (48.6)                    | Immune due to hepatitis B vaccination      |
| Anti-HBsAb     | Negative      |                             |                                            |
| Anti-HBcAb     | Positive      |                             |                                            |
| Anti-HBeAb     | Negative      |                             |                                            |
| HBsAg          | Positive      | 1 (1.4)                      | Acutely infected                           |
| Anti-HBsAb     | Negative      |                             |                                            |
| Anti-HBcAb     | Positive      |                             |                                            |
| Anti-HBeAb     | Negative      |                             |                                            |

susceptible, since the persistence of protective anti-HBsAb levels is not always related to the number of years elapsed since vaccination.

Acknowledgments

This research work owes a lot, to many individuals who have helped tremendously at different stages and deserve their due credit and gratitude. The authors would like to thank all the health care workers in the department of microbiology who volunteered and cooperated, to become a part of this study. They gladly acknowledge the love and support of their numerous friends and colleagues (both senior and junior residents). Any acknowledgement that they make would not be complete without appreciating the role of their institution (Maulana Azad Medical College). Heartfelt gratitude goes to each and every person of their department who offered his or her services.

References

[1] F. Averhoff, F. Mahoney, P. Coleman, G. Schatz, E. Hurwitz, and H. Margolis, “Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection,” American Journal of Preventive Medicine, vol. 15, no. 1, pp. 1–8, 1998.
[2] E. B. Byrne, “Viral hepatitis an occupational hazard of medical personnel. Experience of the Yalenew Haven Hospital, 1952 to 1965,” Journal of the American Medical Association, vol. 195, no. 5, pp. 362–364, 1966.
[3] CDC. Morbidity Mortality Weekly Reports. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and
Recommendations for Postexposure Prophylaxis, pp. 1–42, 2001, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr501-1a1.htm.

[4] L. A. S. Ciorli and D. M. T. Zanetta, “Hepatitis B in healthcare workers: prevalence, vaccination and relation to occupational factors,” Brazilian Journal of Infectious Diseases, vol. 9, no. 5, pp. 384–389, 2005.

[5] E. Dannetun, A. Tegnell, A. Torner, and J. Giesecke, “Coverage of hepatitis B vaccination in Swedish healthcare workers,” Journal of Hospital Infection, vol. 63, no. 2, pp. 201–204, 2006.

[6] EPINET, “Needle stick prevention devices,” Health Devices, vol. 28, pp. 381–407, 1999.

[7] European Consensus Group on Hepatitis B Immunity, “Are booster immunizations needed for lifelong hepatitis B immunity?” The Lancet, vol. 355, pp. 561–565, 2000.

[8] D. FitzSimons, G. François, G. De Carli et al., “Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries,” Occupational and Environmental Medicine, vol. 65, no. 7, pp. 446–451, 2008.

[9] S. Gupta, R. Gupta, Y. K. Joshi, and S. Singh, “Role of horizontal transmission in hepatitis B virus spread among household contacts in north India,” Intervirology, vol. 51, no. 1, pp. 7–13, 2008.

[10] S. Plotkin, E. Leuridan, and P. Van Damme, “Hepatitis B and the need for a booster dose,” Clinical Infectious Diseases, vol. 53, no. 1, pp. 68–75, 2011.

[11] F. J. Mahoney, K. Stewart, H. Hu, P. Coleman, and M. J. Alter, “Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States,” Archives of Internal Medicine, vol. 157, no. 22, pp. 2601–2605, 1997.

[12] M. Saberifroozi, S. Gholamzadeh, and A. R. Serati, “The long-term immunity among health care workers vaccinated against hepatitis B virus in large referral hospital in southern Iran,” Archives of Iranian Medicine, vol. 9, no. 3, pp. 204–207, 2006.

[13] K. A. Sepkowitz, “Occupationally acquired infections in health care workers: part II,” Annals of Internal Medicine, vol. 125, no. 11, pp. 917–928, 1996.

[14] G. Singh, M. P. Singh, I. Walia, C. Sarin, and R. K. Ratho, “Screening for hepatitis B and C viral markers among nursing students in a tertiary care hospital,” Indian Journal of Medical Microbiology, vol. 28, no. 1, pp. 78–79, 2010.

[15] V. Singhal, D. Bora, and S. Singh, “Hepatitis B in health care workers: Indian scenario,” Journal of Laboratory Physicians, vol. 1, no. 2, pp. 41–48, 2009.

[16] V. Singhal, D. Bora, and S. Singh, “Prevalence of hepatitis B virus infection in healthcare workers of a tertiary care centre in India and their vaccination status,” Journal of Vaccines & Vaccination, vol. 2, no. 2, p. 118.

[17] Sukriti, N. T. Pati, A. Sethi et al., “Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India,” Journal of Gastroenterology and Hepatology, vol. 23, no. 11, pp. 1710–1715, 2008.

[18] G. Quaglio, F. Lugoboni, S. Vento et al., “Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated?” Clinical Infectious Disease, vol. 32, no. 10, pp. E143–E144, 2001.

[19] B. J. McMahon, A. J. Parkinson, C. Helminiak et al., “Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen,” Gastroenterology, vol. 103, no. 2, pp. 590–594, 1992.